BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 12086882)

  • 1. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.
    Sawyers CL
    Cancer Cell; 2002 Feb; 1(1):13-5. PubMed ID: 12086882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on the development of a molecularly targeted agent.
    Druker BJ
    Cancer Cell; 2002 Feb; 1(1):31-6. PubMed ID: 12086885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic myeloid leukemia. Sceptical scientists.
    Druker BJ
    Lancet; 2001 Dec; 358 Suppl():S11. PubMed ID: 11784560
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
    Roumiantsev S; Shah NP; Gorre ME; Nicoll J; Brasher BB; Sawyers CL; Van Etten RA
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10700-5. PubMed ID: 12149456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
    O'Dwyer ME; Druker BJ
    Lancet Oncol; 2000 Dec; 1():207-11. PubMed ID: 11905636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer.
    O'Dwyer ME; Druker BJ
    Curr Cancer Drug Targets; 2001 May; 1(1):49-57. PubMed ID: 12188891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myelogenous leukaemia--new therapeutic principles.
    O'Dwyer ME; Druker BJ
    J Intern Med; 2001 Jul; 250(1):3-9. PubMed ID: 11454136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract]   [Full Text] [Related]  

  • 9. Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia.
    O'Dwyer ME; Druker BJ
    Curr Opin Oncol; 2000 Nov; 12(6):594-7. PubMed ID: 11085460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.
    Cowan-Jacob SW; Guez V; Fendrich G; Griffin JD; Fabbro D; Furet P; Liebetanz J; Mestan J; Manley PW
    Mini Rev Med Chem; 2004 Mar; 4(3):285-99. PubMed ID: 15032675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.
    Irving JA; O'Brien S; Lennard AL; Minto L; Lin F; Hall AG
    Clin Chem; 2004 Jul; 50(7):1233-7. PubMed ID: 15229152
    [No Abstract]   [Full Text] [Related]  

  • 12. ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy.
    Mauro MJ; O'Dwyer ME; Druker BJ
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S77-8. PubMed ID: 11587372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thriving with chronic myeloid leukaemia.
    Morris RH
    Lancet; 2001 Dec; 358 Suppl():S12. PubMed ID: 11784561
    [No Abstract]   [Full Text] [Related]  

  • 14. STI571: a gene product-targeted therapy for leukemia.
    Mauro MJ; Druker BJ
    Curr Oncol Rep; 2001 May; 3(3):223-7. PubMed ID: 11296132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STI571 (Gleevec) as a paradigm for cancer therapy.
    Druker BJ
    Trends Mol Med; 2002; 8(4 Suppl):S14-8. PubMed ID: 11927282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    Goldman JM; Melo JV
    N Engl J Med; 2001 Apr; 344(14):1084-6. PubMed ID: 11287980
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
    Melo JV; Chuah C
    Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
    Sawyers CL
    Semin Hematol; 2001 Jul; 38(3 Suppl 8):15-21. PubMed ID: 11526597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STI571: a magic bullet?
    Verweij J; Judson I; van Oosterom A
    Eur J Cancer; 2001 Oct; 37(15):1816-9. PubMed ID: 11576833
    [No Abstract]   [Full Text] [Related]  

  • 20. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.
    Manley PW; Cowan-Jacob SW; Mestan J
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):3-13. PubMed ID: 16172030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.